By customizing treatment for each person, we can get the best results and help them stay healthy long-term
Pictured: Sign at Pfizers headquarters in New York/iStock, JHVEPhoto Pfizer on Friday said it is scrapping an investigational twice-daily oral Glucagon-like peptide-1 receptor agonist candidate after topline data from a Phase IIb trial of obese patients without type 2 diabetes showed high rates of adverse events
And you are seeing these results, please drop a comment on YouTube
Among its predecessors, Liraglutide (Victoza, Saxenda), Exenatide (Byetta), Semaglutide (Ozempic, Rybelsus, Wegovy), Lixisenatide (Adlyxin), Dulaglutide ( Trulicity) are GLP-1 receptor agonists,Tirzepatide (Mounjaro) is a GLP-1/GIP dual receptor co-agonist
Another test I use frequently is the Organic Acids Test